TABLE 1.
Parameters | Mean | Range | Distribution | Reference |
---|---|---|---|---|
Survival model of PFS in the full cohort | ||||
Nivolumab + cabozantinib | Shape = 1.569; Scale = 15.064 | — | Log-logistic | Choueiri et al. (2015) |
Sunitinib | Shape = 1.646; Scale = 8.269 | — | Log-logistic | Choueiri et al. (2015) |
Axitinib | Shape = 1.4633; Scale = 6.6318 | — | Log-logistic | National Cancer Institute, (2021) |
Sorafenib | Shape = 2.281 | — | Exponential | (Bhatt and Finelli, 2014; Amzal et al., 2017) |
OS in the best support care | Shape = 1.613; Scale = 13.857 | — | Log-logistic | Sarfaty et al. (2018) |
Probability of treatment discontinuation as a result of AE (%) | ||||
Nivolumab + cabozantinib | 19.7 | — | Beta | Fisher et al. (2013) |
Sunitinib | 16.9 | — | Beta | Fisher et al. (2013) |
Axitinib | 8.49 | — | Beta | National Cancer Institute, (2021) |
Sorafenib | 18.11 | — | Beta | (Bhatt and Finelli, 2014; Amzal et al., 2017) |
Probability of treatment mortality as a result of AE (%) | ||||
Nivolumab + cabozantinib | 0.31 | — | Beta | Choueiri et al. (2015) |
Sunitinib | 0.61 | — | Beta | Choueiri et al. (2015) |
Axitinib | 0 | — | — | National Cancer Institute, (2021) |
Sorafenib | 0.7 | — | Beta | (Bhatt and Finelli, 2014; Amzal et al., 2017) |
Probability of background death | — | — | — | Cella, (2011) |
Drug cost | ||||
Nivolumab 240 mg | 6,849.84 | 5,479.87–8,219.81 | Gamma | Casciano et al. (2011) |
Cabozantinib 60 mg | 491.30 | 393.04–589.56 | Gamma | Motzer et al. (2018) |
Sunitinib 50 mg | 623.08 | 498.46–747.70 | Gamma | Motzer et al. (2018) |
Axitinib 5 mg | 265.05 | 212.04–318.06 | Gamma | Powles et al. (2020) |
Sorafenib 200 mg | 174 | 139.20–208.80 | Gamma | Motzer et al. (2019) |
Cost of best support care | 1,256 | 1,022–1,489 | Gamma | Motzer et al. (2018) |
Management of AEs | ||||
Nivolumab + cabozantinib | 1,214.68 | 971.74–1,457.61 | Gamma | (Choueiri et al., 2015; Choueiri et al., 2017) |
Sunitinib | 6,632.78 | 5,306.22–7,959.34 | Gamma | (Choueiri et al., 2015; Choueiri et al., 2017) |
Axitinib | 4,660.34 | 3,728.27–5,592.41 | Gamma | (Motzer et al., 2015; Motzer et al., 2018; Choueiri et al., 2021; National Cancer Institute, 2021) |
Sorafenib | 2,284.81 | 556.72–835.08 | Gamma | (Bhatt and Finelli, 2014; Amzal et al., 2017; Choueiri et al., 2021) |
Administration cost | ||||
IV infusion, single or initial drug (≤1 h) | 148.3 | 118.64–177.93 | Gamma | National Comprehensive Cancer Network, (2021) |
Utilities | ||||
First-line treatment | 0.82 | 0.65–0.98 | Beta | Choueiri et al. (2017) |
Second-line treatment | 0.77 (SD: 0.24) | 0.616–0.924 | Beta | Neumann et al. (2014) |
Third-line treatment | 0.66 (SD: 0.30) | 0.528–0.792 | Beta | Weinstein et al. (1996) |
Fourth-line treatment, BSC | 0.494 | 0.403–0.570 | Beta | Rini et al. (2011) |
Disutility due to AEs (grade ≥3) | 0.157 | 0.11–0.204 | Beta | Rini et al. (2020) |
Average patient weight (kg) | 70 | 49.0–93.8 | Beta | Powles et al. (2020) |
OS, overall survival; PFS, progression-free survival; AE, adverse event.